Literature DB >> 9568645

Failure of tumor-reactive lymph node cells to kill tumor in the presence of immune-suppressive CD34+ cells can be overcome with vitamin D3 treatment to diminish CD34+ cell levels.

K Wiers1, M A Wright, K Vellody, M R Young.   

Abstract

Growth of Lewis lung carcinoma (LLC-LN7) tumors results in an increase in CD34+ granulocyte-macrophage progenitor cells having natural suppressor (NS) activity. These CD34+ NS cells were capable of inhibiting the cytotoxic activity of tumor-reactive lymph node cells. In vivo studies showed that adoptive treatment of LLC-LN7 tumor-bearing mice with tumor-reactive lymph node cells plus IL-2 failed to reduce the development of metastases. Studies were conducted to determine if diminishing the levels of CD34+ NS cells would allow for improved anti-tumor effectiveness of the adoptively transferred cells. The suppressive activity of CD34+ cells toward the cytolytic activity of tumor-reactive lymph node cells could be blocked by in vitro culture of CD34+ cells with the differentiation-inducing hormone 1alpha,25-dihydroxyvitamin D3. Similarly, treatment of LLC-LN7-bearing mice with vitamin D3 alone diminished the levels of CD34+ NS cells within regional lymph nodes, spleens and tumors. This treatment resulted in an increased immune reactivity to autologous tumor, as shown by the production of IFN-gamma by lymph node cells in response to the presence of LLC-LN7 cells. The extent of tumor metastasis in mice receiving vitamin D3 treatment was also reduced. When tumor-reactive lymph node cells were adoptively transferred into these LLC-LN7-bearing mice that were receiving vitamin D3 treatment, there resulted a pronounced synergistic reduction in tumor metastasis. The results of this study show that treatment of tumor bearers with vitamin D3 to eliminate CD34+ NS cells improves the anti-tumor effectiveness of adoptively transferred tumor-reactive lymph node cells.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9568645     DOI: 10.1023/a:1006501110857

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  40 in total

1.  T-cell subsets and suppressor cells in human bone marrow.

Authors:  I G Schmidt-Wolf; S Dejbakhsh-Jones; N Ginzton; P Greenberg; S Strober
Journal:  Blood       Date:  1992-12-15       Impact factor: 22.113

2.  Development of splenic natural suppressor (NS) cells in Ehrlich tumor-bearing mice.

Authors:  J L Subiza; J E Viñuela; R Rodriguez; J Gil; M A Figueredo; E G De La Concha
Journal:  Int J Cancer       Date:  1989-08-15       Impact factor: 7.396

Review 3.  Reversal of tumor-induced immunosuppression: a new approach to cancer therapy.

Authors:  S Wojtowicz-Praga
Journal:  J Immunother       Date:  1997-05       Impact factor: 4.456

4.  Sequential development of structural and functional alterations in T cells from tumor-bearing mice.

Authors:  M R Correa; A C Ochoa; P Ghosh; H Mizoguchi; L Harvey; D L Longo
Journal:  J Immunol       Date:  1997-06-01       Impact factor: 5.422

5.  Phenotypic and functional differences between human dendritic cells derived in vitro from hematopoietic progenitors and from monocytes/macrophages.

Authors:  P L Triozzi; W Aldrich
Journal:  J Leukoc Biol       Date:  1997-05       Impact factor: 4.962

6.  Vitamin D3 treatment of tumor bearers can stimulate immune competence and reduce tumor growth when treatment coincides with a heightened presence of natural suppressor cells.

Authors:  M R Young; Y Lozano; J Ihm; M A Wright; M M Prechel
Journal:  Cancer Lett       Date:  1996-07-12       Impact factor: 8.679

7.  Synergism of interleukin 6 and 1 alpha,25-dihydroxyvitamin D3 in induction of myeloid differentiation of human leukemic cell lines.

Authors:  A J Duits; W Dimjati; J G van de Winkel; P J Capel
Journal:  J Leukoc Biol       Date:  1992-03       Impact factor: 4.962

8.  Tumor-induced regulation of suppressor macrophage nitric oxide and TNF-alpha production. Role of tumor-derived IL-10, TGF-beta, and prostaglandin E2.

Authors:  D G Alleva; C J Burger; K D Elgert
Journal:  J Immunol       Date:  1994-08-15       Impact factor: 5.422

9.  Mechanisms of immune suppression in patients with head and neck cancer: presence of CD34(+) cells which suppress immune functions within cancers that secrete granulocyte-macrophage colony-stimulating factor.

Authors:  A S Pak; M A Wright; J P Matthews; S L Collins; G J Petruzzelli; M R Young
Journal:  Clin Cancer Res       Date:  1995-01       Impact factor: 12.531

10.  Heterogeneity of splenic natural suppressor cells induced in mice by treatment with cyclophosphamide.

Authors:  J C Brooks-Kaiser; L A Bourque; D W Hoskin
Journal:  Immunopharmacology       Date:  1993 Mar-Apr
View more
  6 in total

1.  NK depletion results in increased CCL22 secretion and Treg levels in Lewis lung carcinoma via the accumulation of CCL22-secreting CD11b+CD11c+ cells.

Authors:  Adam W Mailloux; Anna-Maria A Clark; M Rita I Young
Journal:  Int J Cancer       Date:  2010-12-01       Impact factor: 7.396

2.  Chemoattraction of femoral CD34+ progenitor cells by tumor-derived vascular endothelial cell growth factor.

Authors:  M R Young; K Kolesiak; M A Wright; D I Gabrilovich
Journal:  Clin Exp Metastasis       Date:  1999       Impact factor: 5.150

Review 3.  Regulatory myeloid cells in transplantation.

Authors:  Brian R Rosborough; Dàlia Raïch-Regué; Heth R Turnquist; Angus W Thomson
Journal:  Transplantation       Date:  2014-02-27       Impact factor: 4.939

4.  1alpha,25-Dihydroxyvitamin D(3) to skew intratumoral levels of immune inhibitory CD34(+) progenitor cells into dendritic cells.

Authors:  Jonathan S Kulbersh; Terry A Day; M Boyd Gillespie; M Rita I Young
Journal:  Otolaryngol Head Neck Surg       Date:  2009-02       Impact factor: 3.497

5.  1α, 25 Dihydroxyvitamin D (1,25(OH)2D) inhibits the T cell suppressive function of myeloid derived suppressor cells (MDSC).

Authors:  J C Fleet; G N Burcham; R D Calvert; B D Elzey; T L Ratliff
Journal:  J Steroid Biochem Mol Biol       Date:  2019-11-26       Impact factor: 4.292

Review 6.  The immune system and head and neck squamous cell carcinoma: from carcinogenesis to new therapeutic opportunities.

Authors:  Monika E Freiser; Paolo Serafini; Donald T Weed
Journal:  Immunol Res       Date:  2013-12       Impact factor: 4.505

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.